Revised SPC: Keytruda (pembrolizumab) 25 mg/mL concentrate for solution for infusion

SPC notes that pembrolizumab is now licensed as monotherapy for the first‑line treatment of metastatic microsatellite instability‑high or mismatch repair deficient colorectal cancer in adults.

electronic Medicines compendium